Cencora Inc.宣布与吉利德科学旗下公司Kite达成一项协议,将支持Kite旗下两款已获美国食品药品监督管理局批准的CAR-T细胞疗法——Yescarta与Tecartus——在美国市场的分销工作。该合作旨在强化这些创新癌症疗法的供应链与可及性。
Cencora Inc.宣布与吉利德科学旗下公司Kite达成一项协议,将支持Kite旗下两款已获美国食品药品监督管理局批准的CAR-T细胞疗法——Yescarta与Tecartus——在美国市场的分销工作。该合作旨在强化这些创新癌症疗法的供应链与可及性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.